Editax -N-8 (Buprenorphine & Naloxone Tablet) 8mg/2mg

Editax -N-8 is a buprenorphine and naloxone combination tablet used for opioid dependence management. This 8mg/2mg strength formulation supports pain relief and withdrawal symptom control. Suitable for ambient storage, it is commonly prescribed in opioid replacement therapy. Ideal for those seeking opioid dependence treatment options.

Strength

8mg/2mg

Pack Size

100s

Storage

Ambient

Manufacturer / TM Owner

Omega Pharmaceuticals

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Editax -N-8 combines buprenorphine and naloxone to help manage opioid dependence and reduce withdrawal symptoms. Buprenorphine, a partial opioid agonist, alleviates cravings while naloxone, an opioid antagonist, discourages misuse by blocking opioid effects. This combination is often used as part of a comprehensive treatment plan for individuals recovering from opioid addiction. It may also provide pain relief in certain cases.

Side Effects

Users of Editax -N-8 may experience reduced opioid cravings and withdrawal symptoms, contributing to stabilization during recovery. Some individuals report improved mood and daily functioning as dependence symptoms lessen. Common effects include mild drowsiness or dizziness, especially when starting treatment. These effects typically diminish as the body adjusts to the medication.

Precautions & Warnings

Editax -N-8 should be stored at room temperature and kept out of reach of children and pets. It is important to follow the prescribed dosage and not to share this medication with others. Avoid alcohol and other central nervous system depressants unless directed by a healthcare professional. Regular medical supervision is recommended to monitor progress and adjust treatment as needed.

Avoid Interactions

Editax -N-8 may interact with alcohol, benzodiazepines, or other sedatives, increasing the risk of drowsiness or respiratory depression. CYP3A4 inhibitors or inducers can affect buprenorphine levels in the body, potentially altering its effectiveness. Inform your healthcare provider about all medications, supplements, or herbal products you are taking to avoid unintended interactions.

References

Frequently Asked Questions

Editax -N-8 is used to manage opioid dependence and reduce withdrawal symptoms as part of a treatment plan.

Store Editax -N-8 at room temperature, away from moisture and direct light.

Avoid alcohol while taking Editax -N-8, as it may increase side effects like drowsiness.

Consult a healthcare provider before using Editax -N-8 if pregnant or breastfeeding.

Common side effects may include drowsiness, dizziness, or headache.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.